剂量密集型新辅助双周白蛋白结合型紫杉醇序贯表柔比星-环磷酰胺对比双周多西他赛序贯表柔比星-环磷酰胺用于激素受体阳性/人表皮生长因子受体2阴性早期乳腺癌患者:一项多中心、随机、III期试验。
完整摘要 · 中文译文
背景:剂量密集型辅助化疗可延长乳腺癌患者的生存期,并已被转化应用于新辅助治疗。尽管每周一次的白蛋白结合型(nab)紫杉醇相比溶剂型紫杉醇可获得更优的病理完全缓解(pCR)率,但支持将其纳入剂量密集型新辅助方案——尤其是用于激素受体阳性/人表皮生长因子受体2阴性(HR+/HER2-)肿瘤——的数据仍然有限。因此,本试验评估了每两周一次剂量密集型nab-紫杉醇方案与相应剂量密集型多西他赛方案相比,是否能提高残存肿瘤负荷(RCB)0/Ⅰ的比例,两者随后均接受剂量密集型表柔比星联合环磷酰胺治疗。 方法:这是一项在中国三家医院开展的多中心、随机、III期试验。HR⁺/HER2⁻患者(cT1-3/N0-1/M0)采用动态分配法按1:1随机分组,并根据Ki-67和TNM分期采用Pocock最小化法进行平衡。试验组接受nab-紫杉醇260 mg/m²静脉给药,第1天给药,每两周一次,共4个周期;对照组接受多西他赛100 mg/m²,给药方案相同。两组患者随后均接受表柔比星90 mg/m²联合环磷酰胺600 mg/m²静脉给药,第1天给药,每两周一次,共4个周期。主要终点为RCB 0/Ⅰ率;次要终点包括无病生存期(DFS)、总生存期(OS)和安全性。 结果:2019年12月至2020年12月期间,共入组388例患者(每组194例)。nab-紫杉醇组的RCB 0/Ⅰ率为20.1%(95% CI 14.41- 26.72),显著超过多西他赛组的11.34%(95% CI 6.92-15.81;χ²=5.62,P = 0.018)。白蛋白结合型紫杉醇组的pCR率为15.98%(95% CI 10.81-21.16),多西他赛组为10.31%(95% CI 6.01-14.60)(χ²=2.73,P = 0.098)。多因素分析证实白蛋白结合型紫杉醇对RCB 0/Ⅰ具有统计学显著的有利影响。五年DFS相当(90.21% vs. 87.11%;HR:1.14,95% CI 0.64-2.05;P = 0.656),五年OS亦相当(96.34% vs. 95.31%;HR:0.64,95% CI 0.29-1.42;P = 0.274),表明无显著生存差异。3/4级不良事件发生率相似(30% vs. 38%)。最常见的全级别毒性(中性粒细胞减少、恶心、肌痛)发生率相当;然而,3/4级外周感觉神经病变仅见于白蛋白结合型紫杉醇队列。未报告治疗相关死亡。 结论:每两周剂量密集白蛋白结合型紫杉醇方案序贯剂量密集表柔比星-环磷酰胺方案构成一种可行且有效的早期HR+/HER2-乳腺癌新辅助治疗策略,在不损害总体安全性的情况下提供了更高的RCB 0/Ⅰ率。高级别外周神经病变发生率增加要求警惕监测,但该方案是对当代新辅助治疗选择的有价值补充。 试验注册:ClinicalTrials.gov ID:NCT04182568,注册日期:2019-08-21。
完整摘要 · 英文原文
BACKGROUND: Dose-dense adjuvant chemotherapy prolongs survival in breast cancer and has been translated into neoadjuvant settings. Although weekly nanoparticle albumin-bound (nab)-paclitaxel yields superior pathological complete response (pCR) rates relative to solvent-based paclitaxel, data supporting its incorporation into a dose-dense neoadjuvant regimen-particularly for hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) tumours-remain limited. This trial therefore evaluated whether a bi-weekly dose-dense nab-paclitaxel schedule improves the proportion of residual cancer burden (RCB) 0/Ⅰ compared with a comparable dose-dense docetaxel regimen, each followed by dose-dense epirubicin plus cyclophosphamide. METHODS: This was a multicentre, randomised, phase III trial done at three hospitals in China. HR⁺/HER2⁻ patients (cT1-3/N0-1/M0) were randomised 1:1 using dynamic allocation with Pocock minimisation on Ki-67 and TNM stage. The experimental arm received nab-paclitaxel 260 mg/m² intravenously on day 1 every two weeks for four cycles; the control arm received docetaxel 100 mg/m² on the identical schedule. Both cohorts subsequently received epirubicin 90 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 every two weeks for four cycles. Primary endpoints were RCB 0/Ⅰ rate; secondary endpoints encompassed disease free survival (DFS), overall survival (OS), and safety. RESULTS: Between December 2019 and December 2020, 388 patients (194 per arm) were enrolled. The nab-paclitaxel arm attained an RCB 0/Ⅰ rate of 20.1% (95% CI 14.41-26.72), significantly exceeding the docetaxel arm's 11.34% (95% CI 6.92-15.81; χ²=5.62, P = 0.018). pCR was achieved in 15.98% (95% CI 10.81-21.16) of the nab-paclitaxel group versus 10.31% (95% CI 6.01-14.60) of the docetaxel group (χ²=2.73, P = 0.098). Multivariate analysis confirmed a statistically significant favourable impact of nab-paclitaxel on RCB 0/Ⅰ. Five-year DFS was comparable (90.21% vs. 87.11%; HR: 1.14, 95% CI 0.64-2.05; P = 0.656), as was five-year OS (96.34% vs. 95.31%; HR: 0.64, 95% CI 0.29-1.42; P = 0.274), indicating no significant survival disparity. Grade 3/4 adverse event incidence was similar (30% vs. 38%). The most frequent all-grade toxicities (neutropenia, nausea, myalgia) occurred at comparable rates; however, grade 3/4 peripheral sensory neuropathy was observed exclusively in the nab-paclitaxel cohort. No treatment-related mortality was reported. CONCLUSIONS: A bi-weekly dose-dense nab-paclitaxel regimen followed by dose-dense epirubicin-cyclophosphamide constitutes a feasible and efficacious neoadjuvant strategy for early stage HR+/HER2- breast cancer, delivering a higher RCB 0/Ⅰ rate without compromising overall safety. The increased incidence of high-grade peripheral neuropathy mandates vigilant monitoring, yet the regimen represents a valuable addition to contemporary neoadjuvant options. TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT04182568, Date of registration: 2019-08-21.